Intra-Cellular Therapies Reports Fourth Quarter and Full-Year 2024 Financial Results
Intra-Cellular Therapies, Inc. Fourth quarter 2024 CAPLYTA net product sales grew to $199.2 million, representing a 51% increase over the same period in 2023. Full year 2024 CAPLY ...
Bristol-Myers Squibb Stock: A Strong Buy Amid Oncology Success
Bristol-Myers Squibb released financial results for Q4 2024. Check out why I am upgrading BMY stock's rating from 'Buy' to ...